Retatrutide Research Guide — Triple Agonist Peptide (LY3437943)

What Is Retatrutide?

Retatrutide — developmental identifier LY3437943 — is a synthetic 39-amino-acid peptide developed as a next-generation incretin-family research compound. Structurally, it is derived from the glucose-dependent insulinotropic polypeptide (GIP) scaffold and carries a C-20 fatty diacid moiety that extends its plasma half-life through reversible albumin binding, analogous to the modification strategy used in semaglutide and tirzepatide.

On research-use-only supplier catalogs, the compound appears under several interchangeable names: the INN retatrutide, the Eli Lilly code LY3437943, or occasionally as a descriptive label such as "GLP-1/GIP/glucagon triple agonist peptide." All refer to the same defined molecular entity with a theoretical monoisotopic mass of approximately 4731 Da.

Mechanism of Action: A Triple Agonist

Retatrutide is characterized in the published literature as a triple agonist — a single molecule engineered to activate three distinct incretin-family receptors:

• GLP-1 receptor (GLP-1R) — glucose-dependent insulin secretion, slowing of gastric emptying, and central appetite modulation.
• GIP receptor (GIPR) — β-cell function, lipid handling in adipose tissue, and complementary incretin signaling.
• Glucagon receptor (GCGR) — hepatic glucose regulation, increased energy expenditure, and lipolytic activity.

The combined engagement of all three receptors distinguishes retatrutide from the single-target GLP-1 agonists (e.g. semaglutide) and dual GLP-1/GIP agonists (e.g. tirzepatide). This polypharmacology is the primary reason retatrutide has become a reference compound in preclinical models of metabolic and body-composition research.

Retatrutide vs. Semaglutide vs. Tirzepatide

Researchers comparing incretin analogs in receptor-binding, cAMP, or β-arrestin recruitment assays typically frame the three compounds on a receptor-selectivity spectrum:

• Semaglutide — mono-agonist, selective for GLP-1R.
• Tirzepatide — dual agonist at GLP-1R and GIPR.
• Retatrutide — triple agonist at GLP-1R, GIPR, and GCGR.

Each compound is available as an in-vitro research peptide, allowing side-by-side characterization of potency (EC₅₀), receptor selectivity, and downstream second-messenger signaling in defined cell-based assays. See the Optimized Aminosshop for related incretin-family reference compounds.

Current Status in Metabolic Research Literature

Retatrutide has been the subject of peer-reviewed reports in journals including the New England Journal of Medicine and The Lancet, describing phase-1 and phase-2 clinical investigations in metabolic-disease cohorts, with additional trials ongoing at the time of writing. Because clinical status evolves rapidly, researchers should consult primary sources — PubMed, ClinicalTrials.gov, and the sponsor's investigator communications — for the current state of the evidence.

Importantly, retatrutide is not an approved medication in any jurisdiction. All in-catalog availability is strictly for in-vitro laboratory and analytical use.

Laboratory Nomenclature and Identification

When sourcing Retatrutide from a research-use-only supplier, the following identifiers should appear consistently across the label, packing slip, and Certificate of Analysis:

• INN: retatrutide
• Developmental code: LY3437943
• Class: GLP-1 / GIP / glucagon receptor triple agonist
• Sequence length: 39 amino acids
• Molecular weight: ~4731 Da (theoretical monoisotopic)
• Form: lyophilized white to off-white powder

Purity, Analytical Standards, and Documentation

Research-grade Retatrutide is supplied at ≥98% purity as measured by reverse-phase HPLC, with identity confirmed by mass spectrometry matching the theoretical molecular weight. A third-party tested Certificate of Analysis should disclose:

• HPLC purity percentage and the analytical column/gradient method.
• Mass-spectrometry-confirmed molecular weight.
• Counterion content (typically trifluoroacetate or acetate).
• Residual solvent and water content by Karl Fischer titration.
• Bacterial endotoxin level, where applicable.

Optimized Aminos publishes third-party tested COAs publicly for every product. Browse them on the contact page.

Handling, Reconstitution, and Storage

Lyophilized Retatrutide is stable at -20 °C or colder, protected from light and moisture. Standard laboratory handling procedure:

1. Allow the sealed vial to equilibrate to room temperature before opening to prevent condensation onto the peptide cake.
2. Reconstitute in sterile bacteriostatic water or an appropriate research-grade solvent under aseptic technique in a laminar-flow cabinet.
3. Swirl gently to dissolve — do not vortex or shake vigorously, which can shear the peptide backbone.
4. Store the reconstituted stock at 2–8 °C for short-term use, or aliquot and freeze at -20 °C or below to minimize freeze-thaw cycles.
5. Discard any preparation showing visible particulates, discoloration, or precipitation.

Regulatory and Ethical Framework

Retatrutide is not a scheduled controlled substance in the United States, but it is not approved by the FDA or any comparable regulator for human or veterinary administration. It is supplied and purchased strictly for in-vitro laboratory research and analytical reference use. Purchasers are responsible for complying with all applicable local, state, federal, institutional, and international regulations governing the acquisition, handling, storage, and disposal of investigational research peptides.

See the full research disclaimer for the terms of use that apply to every compound in the catalog.

Key Takeaways

• Retatrutide (LY3437943) is a synthetic 39-amino-acid triple agonist at GLP-1, GIP, and glucagon receptors.
• On RUO catalogs it appears as "retatrutide" or "LY3437943"; both refer to the same defined molecule (~4731 Da).
• Its triple-agonist pharmacology distinguishes it from GLP-1-only semaglutide and dual-agonist tirzepatide.
• Ongoing peer-reviewed research characterizes its role in metabolic-disease models; it is not an approved medication.
• Research-grade material is ≥98% HPLC pure with a third-party tested Certificate of Analysis, stored lyophilized at -20 °C or colder.
• All availability is strictly for in-vitro laboratory research and analytical use only.